Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

[1]  Zhe Chen,et al.  Chinese a Nti鄄 Cancer a Ssociation , 2022 .

[2]  S. Broder,et al.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. , 2010, Antiviral research.

[3]  T. Hawkins.  Understanding and managing the adverse effects of antiretroviral therapy. , 2010, Antiviral research.

[4]  Luis Menéndez-Arias,et al.  Molecular basis of human immunodeficiency virus drug resistance: an update. , 2010, Antiviral research.

[5]  S. Khoo,et al.  Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. , 2010, Antiviral research.

[6]  E. De Clercq,et al.  Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides. , 2010, Antiviral research.

[7]  Jeffrey N. Martin,et al.  Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients , 2009, AIDS.

[8]  D. Fine,et al.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment , 2009, AIDS.

[9]  T. Larsson,et al.  Profound Antiviral Effect of Oral Administration of MIV-210 on Chronic Hepadnaviral Infection in a Woodchuck Model of Hepatitis B , 2009, Antimicrobial Agents and Chemotherapy.

[10]  H. Mitsuya,et al.  Potent Activity of a Nucleoside Reverse Transcriptase Inhibitor, 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine, against Human Immunodeficiency Virus Type 1 Infection in a Model Using Human Peripheral Blood Mononuclear Cell-Transplanted NOD/SCID Janus Kinase 3 Knockout Mice , 2009, Antimicrobial Agents and Chemotherapy.

[11]  R. Haubrich,et al.  Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment , 2009, AIDS.

[12]  M. Baba,et al.  Retention of Metabolites of 2′,3′-Didehydro-3′-Deoxy-4′-Ethynylthymidine, a Novel Anti-Human Immunodeficiency Virus Type 1 Thymidine Analog, in Cells , 2009, Antimicrobial Agents and Chemotherapy.

[13]  R. Wehr,et al.  Mitochondrial DNA Depletion in Rat Liver Induced by Fosalvudine Tidoxil, a Novel Nucleoside Reverse Transcriptase Inhibitor Prodrug , 2009, Antimicrobial Agents and Chemotherapy.

[14]  J. Deval,et al.  2′-Deoxy-nucleoside Analogs can be Potent Dual Inhibitors of HCV and HIV Replication with Selectivity against Human Polymerases , 2009 .

[15]  M. Baba,et al.  39Study of the Retention of Metabolites of 4′-ED4T, A Novel Anti-HIV-1 Thymidine Analog, in Cells , 2009 .

[16]  G. Painter,et al.  Development of Hexadecyloxypropyl Tenofovir (CMX157) for HIV: Potential for Use as a Microbicide and Therapeutic , 2009 .

[17]  K. Hostetler.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. , 2009, Antiviral research.

[18]  D. Lapierre,et al.  Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects , 2009, Journal of acquired immune deficiency syndromes.

[19]  Yung-chi Cheng,et al.  Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture , 2009, AIDS research and therapy.

[20]  R. Walensky,et al.  HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Hazuda,et al.  The Challenge of Finding a Cure for HIV Infection , 2009, Science.

[22]  S. Cox,et al.  Apricitabine – a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs , 2009 .

[23]  R. Schinazi,et al.  5'-O-Aliphatic and amino acid ester prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity, cytotoxicity and stability studies. , 2009, Bioorganic & medicinal chemistry.

[24]  S. Sarafianos,et al.  Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. , 2009, Journal of molecular biology.

[25]  S. Mallal,et al.  Successful translation of pharmacogenetics into the clinic: the abacavir example. , 2009, Molecular diagnosis & therapy.

[26]  隆夫 二反田.  Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro , 2009 .

[27]  A. Ray,et al.  Metabolism of Antiviral Nucleosides and Nucleotides , 2009 .

[28]  S. Karim,et al.  Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges , 2009 .

[29]  R. Lafemina.  Antiviral research: strategies in antiviral drug discovery. , 2009 .

[30]  G. Rhodes,et al.  Lack of Evidence for an Effect of Lopinavir/Ritonavir on Tenofovir Renal Clearance , 2008, Clinical pharmacology and therapeutics.

[31]  J. Turgeon,et al.  Multiple-Dose Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered over 21 Days with Lopinavir-Ritonavir in Human Immunodeficiency Virus Type 1-Infected Subjects , 2008, Antimicrobial Agents and Chemotherapy.

[32]  D. Cooper,et al.  O414 48-week data from Study AVX-201 – a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance , 2008 .

[33]  R. Mackman,et al.  Novel Nucleotide Human Immunodeficiency Virus Reverse Transcriptase Inhibitor GS-9148 with a Low Nephrotoxic Potential: Characterization of Renal Transport and Accumulation , 2008, Antimicrobial Agents and Chemotherapy.

[34]  E. Dejesus.  Elvucitabine Phase II 48 Week Interim Results Show Safety and Efficacy Profiles Similar to Lamivudine in Treatment Naive HIV-1 Infected Patients with a Unique Pharmacokinetic Profile , 2008 .

[35]  J. Gallant,et al.  The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients , 2008, AIDS.

[36]  J. Lundgren.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients , 2008, AIDS.

[37]  A. Ray,et al.  Effect of Nucleoside and Nucleotide Reverse Transcriptase Inhibitors of HIV on Endogenous Nucleotide Pools , 2008, Antiviral therapy.

[38]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[39]  Lynne Peeples,et al.  Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.

[40]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[41]  Ariana Harari,et al.  Cytidine deamination induced HIV-1 drug resistance , 2008, Proceedings of the National Academy of Sciences.

[42]  M. Baba,et al.  Synthesis and anti-HIV activity of 4'-substituted 4'-thiothymidines: a new entry based on nucleophilic substitution of the 4'-acetoxy group. , 2008, Journal of medicinal chemistry.

[43]  C. Aquilante,et al.  The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV‐infected Patients , 2008, Clinical pharmacology and therapeutics.

[44]  C. Chappey,et al.  Prevalence, Genotypic Associations and Phenotypic Characterization of K65R, L74V and other HIV-1 RT Resistance Mutations in a Commercial Database , 2008, Antiviral therapy.

[45]  Michael Monsour,et al.  Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir , 2008, PLoS medicine.

[46]  B. Gazzard,et al.  Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis , 2008, Journal of acquired immune deficiency syndromes.

[47]  M. Irwin,et al.  2′-Deoxy-4′-azido Nucleoside Analogs Are Highly Potent Inhibitors of Hepatitis C Virus Replication Despite the Lack of 2′-α-Hydroxyl Groups* , 2007, Journal of Biological Chemistry.

[48]  S. Sarafianos,et al.  2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. , 2008, The international journal of biochemistry & cell biology.

[49]  K. White,et al.  Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131 , 2007, Antimicrobial Agents and Chemotherapy.

[50]  R. Mackman,et al.  Intracellular Metabolism of the Nucleotide Prodrug GS-9131, a Potent Anti-Human Immunodeficiency Virus Agent , 2007, Antimicrobial Agents and Chemotherapy.

[51]  Kenneth A. Johnson,et al.  Exonuclease Removal of Dideoxycytidine (Zalcitabine) by the Human Mitochondrial DNA Polymerase , 2007, Antimicrobial Agents and Chemotherapy.

[52]  N. Shaik,et al.  P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution , 2007, Drug Metabolism and Disposition.

[53]  E. De Clercq,et al.  Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections , 2007, Antimicrobial Agents and Chemotherapy.

[54]  J. Mellors,et al.  The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection , 2007, AIDS.

[55]  E. Timmermans,et al.  Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells. , 2007, Antiviral research.

[56]  M. Baba,et al.  Intracellular Metabolism and Persistence of the Anti-Human Immunodeficiency Virus Activity of 2′,3′-Didehydro-3′-Deoxy-4′-Ethynylthymidine, a Novel Thymidine Analog , 2007, Antimicrobial Agents and Chemotherapy.

[57]  M. Wainberg,et al.  Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine , 2007, Antimicrobial Agents and Chemotherapy.

[58]  I. Hidalgo,et al.  Effects of Human Immunodeficiency Virus Protease Inhibitors on the Intestinal Absorption of Tenofovir Disoproxil Fumarate In Vitro , 2007, Antimicrobial Agents and Chemotherapy.

[59]  E. De Clercq,et al.  Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections , 2007, Antimicrobial Agents and Chemotherapy.

[60]  B. Gazzard,et al.  Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir and Vice Versa in HIV-Infected Patients , 2007, Antiviral therapy.

[61]  Guoyu Pan,et al.  Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine , 2007, Drug Metabolism and Disposition.

[62]  Christopher M. Bailey,et al.  Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine , 2007, Antimicrobial Agents and Chemotherapy.

[63]  B. Gazzard,et al.  The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years , 2007, AIDS.

[64]  R. Bethell,et al.  In Vitro Interactions between Apricitabine and Other Deoxycytidine Analogues , 2007, Antimicrobial Agents and Chemotherapy.

[65]  H. McClure,et al.  Pharmacokinetics of the Anti-Human Immunodeficiency Virus Agent 1-(β-d-Dioxolane)Thymine in Rhesus Monkeys , 2007, Antimicrobial Agents and Chemotherapy.

[66]  A. Cheng,et al.  The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients , 2007, HIV clinical trials.

[67]  W. Greene,et al.  APOBEC3G and HIV-1: Strike and counterstrike , 2007, Current HIV/AIDS reports.

[68]  R. Schinazi,et al.  Biochemical Studies on the Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to 1-(β-d-Dioxolane)Thymine Triphosphate , 2007, Antimicrobial Agents and Chemotherapy.

[69]  C. Katlama,et al.  Antiviral activity of low‐dose alovudine in antiretroviral‐experienced patients: results from a 4‐week randomized, double‐blind, placebo‐controlled dose‐ranging trial * , 2007, HIV medicine.

[70]  D. Cooper,et al.  Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts , 2007, HIV medicine.

[71]  K. Anderson,et al.  Highly selective action of triphosphate metabolite of 4'-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. , 2007, Antiviral research.

[72]  L. Waters,et al.  8th International Congress on Drug Therapy in HIV Infection , 2007 .

[73]  K. GuptaSamir.  Editorial comment: tenofovir-related nephrotoxicity--who's at risk? , 2007 .

[74]  Allan E. Rodriguez,et al.  Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV-Infected Individuals from 40 United States Cities , 2007, HIV clinical trials.

[75]  P. Sax,et al.  Renal safety of tenofovir disoproxil fumarate. , 2007, The AIDS reader.

[76]  T. Cihlar,et al.  Molecular Assessment of the Potential for Renal Drug Interactions between Tenofovir and HIV Protease Inhibitors , 2007, Antiviral therapy.

[77]  Yuichi Sugiyama,et al.  Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir , 2007, Molecular Pharmacology.

[78]  A. Collier,et al.  Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen , 2007, AIDS.

[79]  Delia Susan-Resiga,et al.  Phosphorylation of thymidine and AZT in heart mitochondria , 2007, Cardiovascular Toxicology.

[80]  P. Borst,et al.  Multidrug resistance-associated proteins 3, 4, and 5 , 2007, Pflügers Archiv - European Journal of Physiology.

[81]  C. Leen,et al.  A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy , 2006, AIDS.

[82]  K. Robinson,et al.  Mechanism of Active Renal Tubular Efflux of Tenofovir , 2006, Antimicrobial Agents and Chemotherapy.

[83]  Praphan Phanuphak,et al.  Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients , 2006, AIDS.

[84]  C. Toro,et al.  Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs , 2006, Journal of acquired immune deficiency syndromes.

[85]  R. Schinazi,et al.  Phosphoramidate and phosphate prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies. , 2006, Bioorganic & medicinal chemistry.

[86]  D. Taylor,et al.  In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.

[87]  K. Tashima,et al.  Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[88]  Joel E Gallant,et al.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.

[89]  S. Hammer,et al.  Amdoxovir versus Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1-Infected Subjects Failing Current Therapy (Aactg A5118) , 2005, Antiviral therapy.

[90]  J. Gallant,et al.  Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. , 2005, The Journal of infectious diseases.

[91]  H. Kessler,et al.  Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients , 2005, AIDS.

[92]  N. Parkin,et al.  In Vitro Activity of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor (NRTI), against 215 HIV-1 Isolates Resistant to Other NRTIs , 2005, Antiviral chemistry & chemotherapy.

[93]  J. Mellors,et al.  In Vitro Selection and Analysis of Human Immunodeficiency Virus Type 1 Resistant to Derivatives of β-2′,3′-Didehydro-2′,3′-Dideoxy-5-Fluorocytidine , 2005, Antimicrobial Agents and Chemotherapy.

[94]  B. Kearney,et al.  Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens , 2005, Journal of acquired immune deficiency syndromes.

[95]  M. Otto,et al.  Safety, Pharmacokinetics, and Efficacy of (+/−)-β-2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naïve Human Immunodeficiency Virus-Infected Patients , 2005, Antimicrobial Agents and Chemotherapy.

[96]  K. Anderson,et al.  Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases. , 2005, Antiviral research.

[97]  A. Gall,et al.  KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. , 2005, Antiviral research.

[98]  B. Mitchell,et al.  The 5'-nucleotidases as regulators of nucleotide and drug metabolism. , 2005, Pharmacology & therapeutics.

[99]  R. Schinazi,et al.  Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism. , 2005, Journal of medicinal chemistry.

[100]  William A. Lee,et al.  Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue , 2005, Antimicrobial Agents and Chemotherapy.

[101]  B. Clotet,et al.  Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients , 2005, Antimicrobial Agents and Chemotherapy.

[102]  A. Ray.  Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. , 2005, AIDS reviews.

[103]  J. Mellors,et al.  In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase , 2005, Antimicrobial Agents and Chemotherapy.

[104]  E. De Clercq,et al.  Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents. , 2005, Journal of the American Chemical Society.

[105]  E. De Clercq,et al.  Novel Acyclic Nucleoside Phosphonate Analogues with Potent Anti-Hepatitis B Virus Activities , 2005, Antimicrobial Agents and Chemotherapy.

[106]  L. Loeb,et al.  Lethal mutagenesis of HIV. , 2005, Virus research.

[107]  J. Balzarini.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives , 1994, Pharmacy World and Science.

[108]  I. James,et al.  Abacavir stimulates Hsp70 redistribution in Antigen-presenting cells of patients with hypersensitivity: Association with Type-I alcohol dehydrogenase activity , 2005 .

[109]  M. Otto,et al.  Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients. , 2005, Antimicrobial agents and chemotherapy.

[110]  F. Rousseau,et al.  Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.

[111]  K. Borroto-Esoda,et al.  Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5'-phosphates by mammalian phosphotransferases. , 2004, Biochemical pharmacology.

[112]  S. Benkovic,et al.  DNA polymerase fidelity: kinetics, structure, and checkpoints , 2004 .

[113]  B. Kearney,et al.  Intracellular pharmacology of emtricitabine and tenofovir. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[114]  P. Piliero.  Pharmacokinetic Properties of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors , 2004, Journal of acquired immune deficiency syndromes.

[115]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[116]  Terri Wrin,et al.  The prevalence of antiretroviral drug resistance in the United States , 2004, AIDS.

[117]  H. Mitsuya,et al.  Potential of 4′-C-Substituted Nucleosides for the Treatment of HIV-1 , 2004, Antiviral chemistry & chemotherapy.

[118]  V. Calvez,et al.  MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study , 2004, AIDS.

[119]  M. Baba,et al.  Novel 4′-Substituted Stavudine Analog with Improved Anti-Human Immunodeficiency Virus Activity and Decreased Cytotoxicity , 2004, Antimicrobial Agents and Chemotherapy.

[120]  Christopher D Pilcher,et al.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.

[121]  B. Gazzard,et al.  Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase , 2004, AIDS.

[122]  K. Anderson,et al.  Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of 2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine-Triphosphate Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA Polymerase , 2004, Antimicrobial Agents and Chemotherapy.

[123]  A. Ray,et al.  Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir , 2004, Antimicrobial Agents and Chemotherapy.

[124]  K. Anderson,et al.  Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. , 2004, Antiviral research.

[125]  I. James,et al.  Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[126]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). 1983. , 2004, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[127]  Mark A Wainburg.  The impact of the M184V substitution on drug resistance and viral fitness , 2004 .

[128]  S. Mboup,et al.  Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients , 2004, AIDS.

[129]  C. Pannecouque,et al.  Antiviral potential of “new” acyclic nucleoside phosphonates, the 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines , 2004 .

[130]  K. Lichtenstein,et al.  Intracellular pharmacology of emtricitabine and tenofovir. Authors' reply , 2004 .

[131]  M. Wainberg.  The impact of the M184V substitution on drug resistance and viral fitness. , 2004, Expert review of anti-infective therapy.

[132]  Michael D Miller,et al.  K65R, TAMs and tenofovir. , 2004, AIDS reviews.

[133]  Andreas Rolfs,et al.  The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins , 2004, Pflügers Archiv.

[134]  M. Baba,et al.  Synthesis of a highly active new anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine. , 2003, Bioorganic & medicinal chemistry letters.

[135]  C. Fletcher,et al.  Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals , 2003, AIDS.

[136]  E. De Clercq,et al.  5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. , 2003, Journal of medicinal chemistry.

[137]  O. Kirk,et al.  Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine , 2003, AIDS.

[138]  Zhe-Sheng Chen,et al.  MRP8, ATP-binding Cassette C11 (ABCC11), Is a Cyclic Nucleotide Efflux Pump and a Resistance Factor for Fluoropyrimidines 2′,3′-Dideoxycytidine and 9′-(2′-Phosphonylmethoxyethyl)adenine* , 2003, Journal of Biological Chemistry.

[139]  J. Church,et al.  ANTIRETROVIRAL-DRUG RESISTANCE AMONG PATIENTS RECENTLY INFECTED WITH HIV , 2003, Pediatrics.

[140]  L. Naeger,et al.  Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity , 2002, Antimicrobial Agents and Chemotherapy.

[141]  E. De Clercq,et al.  Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates , 2002, Antimicrobial Agents and Chemotherapy.

[142]  J. Montaner,et al.  Intracellular carbovir triphosphate levels in patients taking abacavir once a day. , 2002, AIDS.

[143]  K. Anderson,et al.  Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. , 2002, Biochemistry.

[144]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[145]  T. Cihlar,et al.  Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.

[146]  Wing Lam,et al.  Phosphorylation of Pyrimidine Deoxynucleoside Analog Diphosphates , 2002, The Journal of Biological Chemistry.

[147]  K. Borroto-Esoda,et al.  Dioxolane Guanosine, the Active Form of the Prodrug Diaminopurine Dioxolane, Is a Potent Inhibitor of Drug‐Resistant HIV‐1 Isolates From Patients for Whom Standard Nucleoside Therapy Fails , 2002, Journal of acquired immune deficiency syndromes.

[148]  K. Anderson,et al.  Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase* , 2001, The Journal of Biological Chemistry.

[149]  Alex J White,et al.  Mitochondrial toxicity and HIV therapy , 2001, Sexually transmitted infections.

[150]  T. Cihlar,et al.  NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 641–648 (2001) HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGS , 2003 .

[151]  T. Merigan,et al.  Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants. , 2001, AIDS research and human retroviruses.

[152]  K. Anderson,et al.  Mechanism of Action of 1-β-d-2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1-β-d-Dioxolane Guanosine , 2001, Antimicrobial Agents and Chemotherapy.

[153]  D. Stein,et al.  Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians , 2001, Pharmacotherapy.

[154]  K. Anderson,et al.  Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. , 2001, Antimicrobial agents and chemotherapy.

[155]  A. Karlsson,et al.  Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. , 2000, Pharmacology & therapeutics.

[156]  J. Mellors,et al.  In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β-d-Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine , 2000, Antimicrobial Agents and Chemotherapy.

[157]  D. Richman,et al.  In vivo antagonism with zidovudine plus stavudine combination therapy. , 2000, The Journal of infectious diseases.

[158]  D. Stein,et al.  Pharmacokinetic Interaction of Abacavir (1592U89) and Ethanol in Human Immunodeficiency Virus-Infected Adults , 2000, Antimicrobial Agents and Chemotherapy.

[159]  D. Cooper,et al.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2000, AIDS.

[160]  K. Parnell,et al.  Mechanism of Inhibition of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase by d4TTP: an Equivalent Incorporation Efficiency Relative to the Natural Substrate dTTP , 2000, Antimicrobial Agents and Chemotherapy.

[161]  R. Polk,et al.  Pharmacokinetics of [14C]Abacavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitor, Administered in a Single Oral Dose to HIV-1-Infected Adults: a Mass Balance Study , 1999, Antimicrobial Agents and Chemotherapy.

[162]  M. Wainberg,et al.  Mechanism of Action and In Vitro Activity of 1′,3′-Dioxolanylpurine Nucleoside Analogues against Sensitive and Drug-Resistant Human Immunodeficiency Virus Type 1 Variants , 1999, Antimicrobial Agents and Chemotherapy.

[163]  R. Schinazi,et al.  Mechanistic studies show that (−)‐FTC‐TP is a better inhibitor of HIV‐1 reverse transcriptase than 3TC‐TP , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[164]  J. Schuetz,et al.  MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs , 1999, Nature Medicine.

[165]  A. D. Clark,et al.  Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[166]  M. Wainberg,et al.  Anti-Human Immunodeficiency Virus Type 1 Activity, Intracellular Metabolism, and Pharmacokinetic Evaluation of 2′-Deoxy-3′-Oxa-4′-Thiocytidine , 1999, Antimicrobial Agents and Chemotherapy.

[167]  A. Mian,et al.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. , 1999, Molecular cell.

[168]  T. Steitz.  DNA Polymerases: Structural Diversity and Common Mechanisms* , 1999, The Journal of Biological Chemistry.

[169]  K. Anderson,et al.  Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. , 1999, Biochemistry.

[170]  A. D. Clark,et al.  Sarafianos, S.G. et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with -branched amino acids. Proc. Natl. Acad. Sci. USA 96, 10027-10032 , 1999 .

[171]  J. Mackey,et al.  Nucleoside transporters of mammalian cells. , 1999, Pharmaceutical biotechnology.

[172]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[173]  M. Parniak,et al.  Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. , 1998, Biochemistry.

[174]  Z. Suo,et al.  Selective Inhibition of HIV-1 Reverse Transcriptase by an Antiviral Inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine* , 1998, The Journal of Biological Chemistry.

[175]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.

[176]  A S Perelson,et al.  Drug concentration heterogeneity facilitates the evolution of drug resistance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[177]  M. Kukhanova,et al.  Metabolism of 2′,3′-Dideoxy-2′,3′-Didehydro-β-l(−)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Human Immunodeficiency Virus β-d(+) Nucleoside Analogs In Vitro , 1998, Antimicrobial Agents and Chemotherapy.

[178]  S. Doublié,et al.  Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 Å resolution , 1998, Nature.

[179]  I. Schröder,et al.  Inhibition of human and duck hepatitis B virus by 2',3'-dideoxy-3'-fluoroguanosine in vitro. , 1998, Antiviral research.

[180]  J. Sommadossi.  Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. , 1998, AIDS.

[181]  Samuel H. Wilson,et al.  Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. , 1997, Biochemistry.

[182]  T. Cihlar,et al.  Incorporation of Selected Nucleoside Phosphonates and Anti-Human Immunodeficiency Virus Nucleotide Analogues into DNA by Human DNA Polymerases α, β and γ , 1997 .

[183]  E. Garvey,et al.  Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89 , 1997, Antimicrobial agents and chemotherapy.

[184]  S. Khoo,et al.  In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. , 1997, AIDS research and human retroviruses.

[185]  R. Schinazi,et al.  Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. , 1996, Biochemical pharmacology.

[186]  E. Gullen,et al.  Design and Synthesis of 2‘,3‘-Dideoxy- 2‘,3‘-didehydro-β-l-cytidine (β-l-d4C) and 2‘,3‘-Dideoxy-2‘,3‘-didehydro-β-l-5- fluorocytidine (β-l-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) in Vitro , 1996 .

[187]  J. Janin,et al.  Cellular Phosphorylation of Anti-HIV Nucleosides , 1996, The Journal of Biological Chemistry.

[188]  R. Schinazi,et al.  Selective protection of toxicity of 2',3'-dideoxypyrimidine nucleoside analogs by beta-D-uridine in human granulocyte-macrophage progenitor cells. , 1996, Antiviral research.

[189]  R. Dornsife,et al.  In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans , 1996, Antimicrobial agents and chemotherapy.

[190]  S. Eriksson,et al.  Structure-activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. , 1996, Acta biochimica Polonica.

[191]  H. Conjeevaram,et al.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. , 1995, The New England journal of medicine.

[192]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[193]  Elias S. J. Arnér,et al.  Mammalian deoxyribonucleoside kinases. , 1995, Pharmacology & therapeutics.

[194]  T. Steitz,et al.  A unified polymerase mechanism for nonhomologous DNA and RNA polymerases. , 1994, Science.

[195]  C Flexner,et al.  Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. , 1994, The Journal of infectious diseases.

[196]  J. L. Martin,et al.  Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis , 1994, Antimicrobial Agents and Chemotherapy.

[197]  J. Sommadossi,et al.  Reduction of 3'-azido-2',3'-dideoxynucleosides to their 3'-amino metabolite is mediated by cytochrome P-450 and NADPH-cytochrome P-450 reductase in rat liver microsomes. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[198]  H. McClure,et al.  In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine , 1993, Antimicrobial Agents and Chemotherapy.

[199]  J. Beijnen,et al.  Pharmacokinetic interaction between rifampin and zidovudine , 1993, Antimicrobial Agents and Chemotherapy.

[200]  S. Broder,et al.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.

[201]  R. Schinazi,et al.  Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. , 1993, Biochemical pharmacology.

[202]  R F Schinazi,et al.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides , 1993, Antimicrobial Agents and Chemotherapy.

[203]  K. Anderson,et al.  Mechanism and fidelity of HIV reverse transcriptase. , 1992, The Journal of biological chemistry.

[204]  R F Schinazi,et al.  Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine , 1992, Antimicrobial Agents and Chemotherapy.

[205]  H Zimmermann,et al.  5'-Nucleotidase: molecular structure and functional aspects. , 1992, The Biochemical journal.

[206]  J. Reardon.  Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. , 1992, Biochemistry.

[207]  R. Rydzewski,et al.  Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides. , 1992, Journal of medicinal chemistry.

[208]  T. Chou,et al.  Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine , 1992, Antimicrobial Agents and Chemotherapy.

[209]  C. H. Chen,et al.  The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine. , 1992, The Journal of biological chemistry.

[210]  C. Kim,et al.  Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity Against HIV. , 1991 .

[211]  W. Grody,et al.  Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[212]  S. Broder,et al.  Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. , 1991, Molecular pharmacology.

[213]  C. Kim,et al.  Regiospecific and highly stereoselective electrophilic addition to furanoid glycals: synthesis of phosphonate nucleotide analogs with potent activity against HIV , 1991 .

[214]  H. Reichmann,et al.  Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.

[215]  A. Fridland,et al.  Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. , 1989, Molecular pharmacology.

[216]  H. Ho,et al.  Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus , 1989, Antimicrobial Agents and Chemotherapy.

[217]  T. Spector,et al.  Glucuronidation of 3'-azido-3'-deoxythymidine: human and rat enzyme specificity. , 1989, Biochemical pharmacology.

[218]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[219]  E. De Clercq,et al.  Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides. , 1988, Journal of medicinal chemistry.

[220]  S. Broder,et al.  2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. , 1987, Molecular pharmacology.

[221]  S. Broder,et al.  Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. , 1986, Biochemical pharmacology.

[222]  S. Broder,et al.  Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. , 1987, Biochemical pharmacology.

[223]  Broder,et al.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[224]  D W Barry,et al.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[225]  B. Haynes,et al.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.

[226]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[227]  R. Parks,et al.  Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates. , 1980, Biochemistry.